altiratinib   Click here for help

GtoPdb Ligand ID: 9174

Synonyms: DCC-270 | DCC-2701 | DP-5164
Compound class: Synthetic organic
Comment: Altiratinib is an oral, selective and potent inhibitor of MET, TIE2, VEGFR2 and TRK kinases, being investigated for its potential anticancer activity. This specific compound is claimed in patent WO2016061231 [1], and prior patent submissions.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 7
Hydrogen bond donors 3
Rotatable bonds 11
Topological polar surface area 109.42
Molecular weight 510.15
XLogP 4.17
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES O=C(C1CC1)Nc1nccc(c1)Oc1cc(F)c(cc1F)NC(=O)C1(CC1)C(=O)Nc1ccc(cc1)F
Isomeric SMILES O=C(C1CC1)Nc1nccc(c1)Oc1cc(F)c(cc1F)NC(=O)C1(CC1)C(=O)Nc1ccc(cc1)F
InChI InChI=1S/C26H21F3N4O4/c27-15-3-5-16(6-4-15)31-24(35)26(8-9-26)25(36)32-20-12-19(29)21(13-18(20)28)37-17-7-10-30-22(11-17)33-23(34)14-1-2-14/h3-7,10-14H,1-2,8-9H2,(H,31,35)(H,32,36)(H,30,33,34)
InChI Key GNNDEPIMDAZHRQ-UHFFFAOYSA-N
No information available.
Summary of Clinical Use Click here for help
The US FDA has granted altiratinib Orphan Drug Designation for glioblastoma multiforme (GBM). Phase 1 clinical trial NCT02228811, which was designed to evaluate oral altiratinib monotherapy vs. various locally advanced and metastatic solid tumours was terminated.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT02228811 A Study of DCC-2701 in Participants With Advanced Solid Tumors Phase 1 Interventional Deciphera Pharmaceuticals LLC